711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. - Weickhardt, A.J.; Frentzas, S.; Lemech, C.; Srimani, J.; Yin, J.; Trepicchio, W.L.; Gorgun, C.; Kichenadasse, G. (Annals of Oncology, 2023)